Correction to: Annals of Nuclear Medicine (2022) 36:302–309 https://doi.org/10.1007/s12149-021-01704-6

The authors would like to correct the errors in the original article. The correction details are given below:

The contents of Tables 2, 4 were incorrect. The correct Tables 2 and 4 are given below.

Table 2 SUVmax of the detected lesions at each phase
Full size table
Table 4 Comparison of patient-based detection rates between the treatment methods stratified by tumor location (3 h post-injection)
Full size table

The last sentence under the “Results”, under the subheading “Patient‑based analysis” in page 3 should be “When patients were divided into two groups according to GS, the detection rate in patients with GS of 8 and 9 tended to be higher than that in patients with GS of 6 and 7 [79% (33/42) vs. 60% (18/30)], although this difference was not statistically significant (p = 0.087).”.

The p values were corrected in the subheading “Diagnostic performance according to initial treatment methods” under the “Results” section as given below:

The overall detection rate of recurrence tended to be higher in patients who received RT than those underwent RP (81% (30/37) vs. 60% (21/35), p = 0.049). In patients with PSA levels greater than 0.5 ng/ml, no significant difference in the detection rate was observed between patients who underwent RP and those who received RT (73% (19/26) vs. 81% (30/37), p = 0.452).

The second sentence under the heading “Conclusion” should be deleted.